Hirschey receives the Helmholtz Young Investigator Diabetes Award

blogEntryThumbnailMatthew Hirschey, PhD, assistant professor of medicine (Endocrinology, Metabolism and Nutrition), Pharmacology & Cancer Biology and the Sarah W. Stedman Nutrition & Metabolism Center, was awarded the Helmholtz Young Investigator Diabetes Award (HelDi Award) by the Helmholtz Institute in Munich, Germany, and Nature Medicine. Read More...

Metabolic Homeostasis: HDACs Take Center Stage


Synthetic PPARg ligands (such as TZDs) are currently the most powerful insulin sensitizers in the treatment of type 2 diabetes in clinics. Of two TZD-based medicines (rosiglitazone and pioglitazone), rosiglitazone was withdrawn in the European market last year and will be removed from pharmacy stores in US by this November. The rosiglitazone-associated heart failure is responsible for the end of its market performance in Europe and US. A potential side effect in bladder cancer is another threat to the value of TZD-based medicines for type 2 diabetes. Do scientist have any new leads towards drug targets/candidates to replace TZD-based medicines?